enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Pembrolizumab - Wikipedia

   en.wikipedia.org/wiki/Pembrolizumab

   Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.

3. Merck's Keytruda combo gets FDA nod for expanded use in ... - AOL

   www.aol.com/news/mercks-keytruda-combo-gets-fda...

   The Keytruda combination was approved for patients with cervical cancer who had not previously received surgery, radiation, or systemic therapy, FDA said. This makes Keytruda plus ...

4. PD-1 and PD-L1 inhibitors - Wikipedia

   en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

   Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for ...

5. Merck's Keytruda Secures First FDA-Approval For Rare Form ...

   www.aol.com/mercks-keytruda-secures-first-fda...

   The approval marks the first indication for Keytruda in MPM in the U.S. Also Read: Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study. MPM is a rare ...

6. Merck's Keytruda gets FDA nod for expanded use in lung cancer

   www.aol.com/news/mercks-keytruda-gets-u-fdas...

   Keytruda, Merck's top-selling product approved in multiple indications worldwide, helps the body's own immune system fend off cancer by blocking a protein called PD-1.

7. Checkpoint inhibitor - Wikipedia

   en.wikipedia.org/wiki/Checkpoint_inhibitor

   It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [16] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17]

8. Merck Reveals Mixed Data From Keytruda/Lynparza Regime In ...

   www.aol.com/merck-reveals-mixed-data-keytruda...

   In the U.S., Lynparza has three approved indications in ovarian cancer. Keytruda is not approved to treat ovarian cancer. Sunday, ...

9. Merck's Experimental Favezelimab/Keytruda Combo Fails ... - AOL

   www.aol.com/mercks-experimental-favezelimab...

   Concurrently, on Wednesday, Japan’s drug regulator approved new indications for Keytruda (pembrolizumab), in certain lung and urothelial cancers. Merck Stock Prediction For 2024